Elutia Inc. (ELUT)

NASDAQ: ELUT · IEX Real-Time Price · USD
3.160
+0.010 (0.32%)
Mar 28, 2024, 3:58 PM EDT - Market closed
0.32%
Market Cap 92.79M
Revenue (ttm) 24.75M
Net Income (ttm) -37.66M
Shares Out 18.16M
EPS (ttm) -2.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,595
Open 3.170
Previous Close 3.150
Day's Range 3.160 - 3.240
52-Week Range 1.100 - 4.190
Beta 0.52
Analysts Strong Buy
Price Target 4.50 (+42.41%)
Earnings Date Mar 7, 2024

About ELUT

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Oct 8, 2020
Employees 54
Stock Exchange NASDAQ
Ticker Symbol ELUT
Full Company Profile

Financial Performance

In 2023, Elutia's revenue was $24.75 million, an increase of 3.76% compared to the previous year's $23.85 million. Losses were -$37.66 million, 14.5% more than in 2022.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for ELUT stock is "Strong Buy." The 12-month stock price forecast is $4.5, which is an increase of 42.41% from the latest price.

Price Target
$4.5
(42.41% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Elutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM® Clearance Decision in First Half of 2024

SILVER SPRING, Md., March 07, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today provided a business update and reported financial results for the fourth quarter and...

21 days ago - GlobeNewsWire

Elutia to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 7, 2024

SILVER SPRING, Md., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that it will release its fourth quart...

5 weeks ago - GlobeNewsWire

Elutia Regains Compliance with Nasdaq Listing Requirements

SILVER SPRING, Md., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) today announced that it has regained compliance with Nasdaq's market value of listed securities requirement and majorit...

2 months ago - GlobeNewsWire

Elutia Reports 26% Year-Over-Year Sales Growth of Proprietary Products and Strengthened Balance Sheet in Third Quarter 2023 Financial Results

- Anticipate 510(k) filing for transformational Drug-Eluting Biomatrix CanGarooRM in Fourth Quarter SILVER SPRING, Md., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a compa...

4 months ago - GlobeNewsWire

Elutia Completes Divestiture of Orthobiologics Business Unit for Cash Proceeds of Up to $35 Million

- Company Now Focused on Proprietary Drug-Eluting Biomatrix Platform - SILVER SPRING, Md., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting bi...

5 months ago - GlobeNewsWire

Elutia to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

SILVER SPRING, Md., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that it will release its third quarte...

5 months ago - GlobeNewsWire

Elutia to Participate in a Panel Discussion at the Cantor Global Healthcare Conference

SILVER SPRING, Md., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and ...

6 months ago - GlobeNewsWire

Elutia Announces Private Placement for Proceeds Up to $26 Million

– Combined proceeds of financing and Orthobiologics divestiture potentially top $60 million – SILVER SPRING, Md., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pi...

6 months ago - GlobeNewsWire

Elutia Announces Sale of Orthobiologics Business Unit for Cash Proceeds of Up to $35 Million

SILVER SPRING, Md., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced the divestiture of the Company's Ort...

6 months ago - GlobeNewsWire

Elutia to Present at the H.C. Wainwright 25th Annual Global Investment Conference

SILVER SPRING, Md., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and ...

7 months ago - GlobeNewsWire

Aziyo Biologics Announces Publication of a CanGaroo® Case Study Demonstrating Bioenvelope Benefits for Reoperative Procedures

Case provides first histologic evidence that CanGaroo can catalyze development of new healthy tissue layer within an existing cardiac implantable electronic device (CIED) pocket

7 months ago - GlobeNewsWire

Aziyo Biologics Reports Second Quarter 2023 Financial Results - Transformation Continues to Drug-Eluting Biomatrix Company

Negotiating multiple LOIs to divest Orthopedic business CanGaroo® RM 510(k) resubmission to the FDA remains on track SimpliDerm® quarterly net sales up 32% year-over-year Successful transfer of Cardio...

8 months ago - GlobeNewsWire

Aziyo Biologics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023

SILVER SPRING, Md., July 31, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medi...

8 months ago - GlobeNewsWire

Aziyo Biologics Announces Voluntary Recall of Viable Bone Matrix Products

SILVER SPRING, Md., July 13, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a company that develops and commercializes biologic products to improve compatibility between medical device...

9 months ago - GlobeNewsWire

Aziyo Biologics Presents Positive Clinical Data on CanGaroo® Biologic Envelope

Study Presented at Heart Rhythm Society Supports Wound-Healing Benefits in Patients Receiving Cardiac Implantable Electronic Devices

11 months ago - GlobeNewsWire

Aziyo Biologics Reports Highest Sales and Gross Profit in Company History

- All Four Business Segments Achieved Growth Led by Strong SimpliDerm and CanGaroo Sales - SILVER SPRING, Md., May 10, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a compan...

11 months ago - GlobeNewsWire

Aziyo Biologics to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023

SILVER SPRING, Md., May 03, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medic...

11 months ago - GlobeNewsWire

Aziyo Biologics and LeMaitre Vascular Partner for the Distribution of Aziyo's Cardiovascular Portfolio

SILVER SPRING, Md., April 20, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between med...

1 year ago - GlobeNewsWire

Aziyo Biologics Reports Record Full Year 2022 Revenues

SILVER SPRING, Md., March 22, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between med...

1 year ago - GlobeNewsWire

Aziyo Biologics and Sientra Announce SimpliDerm® Partnership to Improve Women's Access to Biologics for Soft Tissue Reconstruction

SILVER SPRING, Md. and IRVINE, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compat...

1 year ago - GlobeNewsWire

Aziyo Biologics to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 22, 2023

SILVER SPRING, Md., March 15, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between med...

1 year ago - GlobeNewsWire

Aziyo Biologics to Present at the Cowen 43rd Annual Health Care Conference

SILVER SPRING, Md., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medi...

1 year ago - GlobeNewsWire

Aziyo Biologics Announces Record Annual Net Sales in Preliminary (Unaudited) Fourth Quarter and Full Year 2022 Topline Results

SILVER SPRING, Md., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a biologics company with a portfolio of regenerative products aimed at improving compatibility bet...

1 year ago - GlobeNewsWire

Aziyo Biologics Announces Funding of Additional $4 Million Term Loan with SWK Holdings Corporation

Follows recent equity financing, resulting in debt and equity gross proceeds of $15.2 million

1 year ago - GlobeNewsWire

Aziyo Biologics, Inc. Announces Pricing of $11.2 Million Public Offering of Common Stock

SILVER SPRING, Md., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a biologics company with a portfolio of regenerative products aimed at improving compatibility bet...

1 year ago - GlobeNewsWire